5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer (original) (raw)

Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer

Cancer Chemotherapy and Pharmacology, 1986

DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity

Cancer Chemotherapy and Pharmacology, 2011

Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas

F. Rolland

Clinical cancer research : an official journal of the American Association for Cancer Research, 1998

View PDFchevron_right

Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5FU infusion and cisplatin

John Jacobs

Cancer, 1985

View PDFchevron_right

Treatment Outcome of Pharmacokinetics-Based Dosing of Docetaxel and Fluorouracil in Advanced Head and Neck Cancer Patients

Tarek Shouman

Journal of Cancer Therapy

View PDFchevron_right

A phase II evaluation of a 3-hour infusion of paclitaxel (P), cisplatin (CDDP) & 5-fluorouracil (5FU) in patients with advanced or recurrent squamous cell carcinoma of the head & neck (SCCHN): A Southwest Oncology Group Study

Wolfram Samlowski

Journal of Clinical Oncology, 2004

View PDFchevron_right

Systemic Chemotherapy with Cisplatin Plus 5-FU (PF) for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN): Efficacy and Safety of a Lower Dose of PF (80/800) at a Single Institution in Japan

Naomi Kiyota

Japanese Journal of Clinical Oncology, 2009

View PDFchevron_right

Head and neck irradiation modulates pharmacokinetics of 5-fluorouracil and cisplatin

Mei-ling Hou

Journal of Translational Medicine, 2013

View PDFchevron_right

A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck

Stephen Williamson

Cancer, 2006

View PDFchevron_right

Feasibility of concurrent chemoradiotherapy with high-dose cisplatin after induction TPF chemotherapy in head and neck cancer: a critical review of the literature and the experience of the European Institute of Oncology

Giuseppe Fanetti

Medical Oncology, 2017

View PDFchevron_right

Superior clinical response and survival rates with initial bolus of cisplatin and 120 hour infusion of 5-fluorouracil before definitive therapy for locally advanced head and neck cancer

John Jacobs

American Journal of Surgery, 1984

View PDFchevron_right

Adaptive intrapatient dose escalation of cisplatin in patients with advanced head and neck cancer

Marc Maliepaard

Anti-Cancer Drugs, 2001

View PDFchevron_right

Concurrent radiotherapy and continuous ambulatory infusion 5-fluorouracil in advanced head and neck cancer

Kailash Narayan

European Journal of Cancer, 1996

View PDFchevron_right

Neoadjuvant therapy for advanced head and neck cancer with allopurinol-modulated high dose 5-fluorouracil and cisplatin a phase I-II study

David Shimm

Cancer, 1987

View PDFchevron_right

Pharmacokinetic-Based Chemotherapy Dosing in Advanced Head and Neck Cancer: A Mini Review

Ahmed Abo Gabal

Research in Oncology, 2019

View PDFchevron_right

Comparison of acute toxicities of two chemotherapy schedules for head and neck cancers

Subramania Iyer

Journal of Cancer Research and Therapeutics, 2006

View PDFchevron_right

Comparative Study of Weekly and Three Weekly Chemoradiation Regimen in Advanced Head and Neck Cancer at Silchar Medical College

Yousuf Choudhury

International Journal of Science and Research (IJSR), 2017

View PDFchevron_right

Comparison of Safety and Efficacy of Two Different Chemotherapy Dosing Schedules Used in Concurrent Chemoradiation of Head and Neck Cancer: A Retrospective Experience from a Tertiary Cancer Care Institute of Eastern India

Palas De

Asian Pacific journal of cancer care, 2023

View PDFchevron_right

An alternative approach with a low dose and prolonged chemotherapy for palliative treatment of locally advanced, metastatic or recurrent squamous cell head and neck cancer

david Reisman

Applied Cancer Research

View PDFchevron_right

Dose Escalation Study of Nedaplatin with 5-Fluorouracil in Combination with Alternating Radiotherapy in Patients with Head and Neck Cancer

H. Tachibana

Japanese Journal of Clinical Oncology, 2007

View PDFchevron_right

Weekly 5-fluorouracil and folinic acid plus escalating doses of cisplatin with glutathione protection in patients with advanced head and neck cancer

R. Valenza

Medical oncology and tumor pharmacotherapy, 1992

View PDFchevron_right

Induction chemotherapy with cisplatin/docetaxel versus cisplatin/5-fluorouracil for locally advanced squamous cell carcinoma of the head and neck: A randomised phase II study

Antonio Rueda Lara

European Journal of Cancer, 2005

View PDFchevron_right

Toxicity of two cisplatin-based radiochemotherapy regimens for the treatment of patients with stage III/IV head and neck cancer

Steven Schild

Head & Neck, 2008

View PDFchevron_right

Toxicity and preliminary results from a trial of hyperfractionated radiation with or without simultaneous 5-fluorouracil-cisplatin in advanced head and neck squamous cell carcinomas

Harold Pillsbury

Seminars in Radiation Oncology

View PDFchevron_right

No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion

François Demard

British Journal of Cancer, 1992

View PDFchevron_right

5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer (original) (raw)

Related papers